title: Stretch-inducible expression of connective tissue growth factor (CTGF) in human osteoblasts-like cells is mediated by PI3K-JNK pathway.
abstract: To explore the possible role for connective tissue growth factor (CTGF) during tooth movement, we evaluated CTGF gene and protein expression in MG-63 cells subjected to cyclic stretch. Cyclic stretch caused a time-dependent increase in CTGF mRNA and protein levels.Inhibition of p38 MAP kinase or ERK activation did not affect cyclic stretch-induced CTGF expression. Specific inhibitors of PI3K suppressed stretch -induced CTGF expression in a time-dependent manner. cyclic stretch activated JNK and ERK, but not p38 MAP kinase in osteoblast-like cells. PI3K inhibitors suppressed cyclic stretch-induced JNK, but not p38 MAP kinase activation. Finally, SP600125, a Specific Inhibitor of JNK, suppressed stretch -induced CTGF Expression. These results suggest that stretch-induced CTGF expression is mediated through the PI3K-JNK -dependent pathway, not by p38 MAP kinase and ERK pathways.
authors.affiliation: Stomatological Center, the Second Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Li-Wei
authors.initials: LW
authors.lastname: Xiao
authors.forename: Min
authors.initials: M
authors.lastname: Yang
authors.forename: Jing
authors.initials: J
authors.lastname: Dong
authors.forename: Hui
authors.initials: H
authors.lastname: Xie
authors.forename: Guo-Liang
authors.initials: GL
authors.lastname: Sui
authors.forename: Yu-Ling
authors.initials: YL
authors.lastname: He
authors.forename: Jia-Xuan
authors.initials: JX
authors.lastname: Lei
authors.forename: Er-Yuan
authors.initials: EY
authors.lastname: Liao
authors.forename: Xiao
authors.initials: X
authors.lastname: Yuan
mesh_terms: D000873:Anthracenes / Q000494:pharmacology; D002460:Cell Line; D002867:Chromones / Q000494:pharmacology; D055513:Connective Tissue Growth Factor / Q000235:genetics / Q000378:metabolism*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D005419:Flavonoids / Q000494:pharmacology; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D009025:Morpholines / Q000494:pharmacology; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D015398:Signal Transduction; D013314:Stress, Mechanical; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
chemical_list: D000873:Anthracenes; D002867:Chromones; D055513:Connective Tissue Growth Factor; D048049:Extracellular Signal-Regulated MAP Kinases; D005419:Flavonoids; D048031:JNK Mitogen-Activated Protein Kinases; D009025:Morpholines; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D048051:p38 Mitogen-Activated Protein Kinases; C432165:pyrazolanthrone; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one